Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-way Comparison from AUGUSTUS
JACC This Week · American College of Cardiology
August 26, 202410m 37s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr. Valentin Fuster discusses the Augustus trial's groundbreaking findings on antithrombotic strategies for atrial fibrillation patients post-acute coronary syndrome or PCI. The study reveals that a regimen of apixaban and a P2Y12 inhibitor—without aspirin—offers superior safety and efficacy, challenging traditional triple therapy approaches.